KindredBio Board of Directors

Ervin Veszprémi

Ervin Veszprémi

Mr. Veszprémi previously served as the Vice President and Global Head of Marketing at Novartis Animal Health, one of the largest veterinary companies in the world. Prior to that position, he served as the Country Head of Ciba-Geigy Animal Health Spain. He is currently CEO of Medichem, a leading Active Pharmaceutical Product manufacturer, and has almost 30 years of experience in the pharmaceutical industry, including 15 in the animal health sector. Mr. Veszprémi holds a physiology degree from University of British Columbia and has studied management at Harvard Business School and Stanford.

Raymond Townsend, PharmD

Raymond Townsend, PharmD

Dr. Townsend is a pioneer in the pharmacoeconomics field. He was formerly the Worldwide Director and Vice President, Outcomes, Epidemiology and Policy Research at Glaxo. He also served as Senior Vice President, Pharmacoeconomic & Epidemiology Outcomes Research, at Elan Pharmaceuticals, Inc. Dr. Townsend earned a B.A. in Economics at California State University and his Doctor of Pharmacy degree from the University of California, San Francisco.

Herbert D. Montgomery

Herbert D. Montgomery

Mr. Montgomery has extensive experience in finance, including having served as CFO of several public companies, and having taken three companies public. Most recently, he was Vice Chairman of the Board and Executive Officer of Lightpost Holdings, LLC. Prior to that, Mr. Montgomery was Executive Vice President, Chief Financial Officer, and Treasurer of Standard Media International; Senior Vice President, Chief Financial Officer and Treasurer of Cotelligent, Inc.; and Senior Vice President, Chief Financial Officer and Treasurer of Guy F. Atkinson. He holds a Master of Science degree in Management and a Bachelor of Science degree in Finance from California State University, Northridge. Mr. Montgomery was also previously Chairman of the Board of Institute for OneWorld Health.

Ernest Mario, PhD

Ernest Mario, PhD

Dr. Mario served as the Chief Executive and Deputy Chairman of Glaxo from 1989 to 1993, then the second-largest drug company in the world. After Glaxo, he became Chairman and CEO of ALZA Corporation, a drug delivery technology company acquired by Johnson & Johnson for $10.5 Billion in 2001. Dr. Mario subsequently served as Chairman and CEO of Reliant Pharmaceuticals, which was acquired by GlaxoSmithKline. He currently is Chairman of Soleno Therapeutics, a private pharmaceutical company developing novel therapeutic products to treat migraine and allergic rhinitis. He is also a Venture Partner with Pappas Ventures and serves on a number of corporate boards. Dr. Mario earned a B.S. in pharmacy at Rutgers and his M.S. and Ph.D. in physical sciences at the University of Rhode Island. He holds honorary doctorates from URI and Rutgers, the latter of which in 2001 renamed its pharmacy school the Ernest Mario School of Pharmacy. In 2007 he was awarded the Remington Medal by the American Pharmacists‘ Association, pharmacy’s highest honor.

Joseph S. McCracken DVM, MS

Joseph S. McCracken DVM, MS

Dr. McCracken was previously Vice President and Global Head of Business Development & Licensing for Roche Pharma where he was responsible for Roche Pharma’s global in-licensing and out-licensing activities. Prior to joining Roche Pharma, Dr. McCracken held the position of Vice President, Business Development at Genentech for more than 10 years, and previously held similar positions at Aventis Pharma and Rhone-Poulenc Rorer. He currently serves on the boards of Alkahest, Inc., Savara Pharmaceuticals, and Regimmune Inc. Dr. McCracken holds a B.S. in Microbiology, an M.S. in Pharmacology, and a Doctor of Veterinary Medicine from Ohio State University.

Richard Chin, MD

Richard Chin, MD

Founder and Chief Executive Officer

Richard Chin is a Harvard-trained physician and a former Rhodes Scholar with a track record of almost a dozen drug approvals and over 50 INDs. Drugs Richard developed, including Lucentis®, Xolair®, Tysabri®, and Rituxan® for immune diseases, have current aggregate sales of well over $10 billion per year.

Previously, Richard was Head of Clinical Research for the Biotherapeutics Unit at Genentech where he oversaw all of Genentech’s drug development programs except oncology products; Senior VP of Global Development at Elan; CEO of Oxigene, a NASDAQ-listed biotechnology company; and CEO of OneWorld Health, a Gates Foundation-funded nonprofit developing drugs for impoverished patients in developing countries. Richard was named by BusinessWeek in 2006 as one of 99 youngest public company CEOs in the United States. He has authored several major textbooks on clinical development and teaches drug development at UCSF.

Denise Bevers

Denise Bevers

Founder, President, and Chief Operating Officer

Denise Bevers is an experienced pharmaceutical executive with a distinguished career in clinical operations, medical affairs, and scientific communications. With over 20 years of pharmaceutical and research experience, she has successfully managed dozens of product launches and development programs from Phase I through Phase IV. Ms. Bevers previously held leadership positions at Elan Pharmaceuticals, Scripps Clinic and Research Foundation, Quintiles, and SkyePharma. Prior to co-founding KindredBio, she was President and Founding Partner of SD Scientific, a full-service medical affairs and communications company.